Fig. 7.

E0771 tumor volume multiplicity decreases with TAM depletion or TNF-$\alpha$ knockout, but the effects are not synergistic. After 27 days, E0771 tumors grown in wild-type mice on PBSL therapy ($n=21$) were larger than those grown in wild-type mice on ClodL therapy ($n=16$), as well as those grown in TNF-$\alpha$ knockout mice exposed to either PBSL or ClodL ($p<0.05$, $n=15$ for both). No other group was found significantly different from another at 27 days, and no significant differences in tumor volume multiplicity were found at earlier timepoints ($p>0.05$). Tumor growth was assessed by normalizing measurements to tumor size at day 3 (i.e., tumor volume multiplicity) to minimize the possibility that slightly different numbers of cells may have been injected despite constant injection volumes and cell densities.